La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Pasithea Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Pasithea Therapeutics..

Pasithea Therapeutics (NASDAQ:KTTA) Azioni, Catena delle Opzioni

Pasithea Therapeutics

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics Corp

Zions Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) reported quarterly earnings of $1.13 per share which missed the analyst consensus estimate of $1.17 by 3.42 percent.

Earnings

Earnings Misses

News

ZION

Zions Bancorp Q1 2025 GAAP EPS $1.13 Misses $1.17 Estimate

Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) shares are trading lower Monday after Benchmark lowered its price target on the stock <a href="https://www.benzinga.com/tech/25/04/44896693/boeing-secures-new-stocks-of-crucial-nuts-and-bolts-used-in-737-max-production-amid-chinas-import-ban-report">from $250 to $215.</a>
What To Know: The firm still maintains a Buy rating, but the reduction reflects growing concern over Boeing's ongoing production issues and a challenging operating environment.
According to Benchmark's first-quarter 2025 preview, Boeing is facing multiple short-term disruptions, including persistent supply chain problems, regulatory uncertainties and tariff-related complexity. A fire at a major fastener supplier and issues with GE engines have only worsened delays, making it difficult for the company to meet delivery expectations.
The report emphasizes that Boeing is still producing below long-term demand levels, suggesting the real issue isn't demand but rather the company's inability to ramp up supply. Analysts highlighted that while the long-term fundamentals remain intact — especially the duopoly with Airbus — the path to recovery is taking longer than previously expected. Ongoing complications, such as FAA hurdles and internal production setbacks, continue to weigh on investor sentiment.
Despite the challenges, Benchmark remains positive on Boeing&#8217;s long-term free cash flow trajectory, though it now sees slower momentum in the near term. The firm lowered its price target accordingly to reflect the new timeline for improvement, cutting it by $35. 
BA Price Action: Boeing shares were down 1.58% at $159.34 at the time of publication Monday, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"><img loading="lazy" decoding="async" width="1024" height="535" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21154030/Screenshot-2025-04-21-at-15.40.05-1024x535.png" alt="" class="wp-image-880617" style="width:388px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21154030/Screenshot-2025-04-21-at-15.40.05-1024x535.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21154030/Screenshot-2025-04-21-at-15.40.05-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21154030/Screenshot-2025-04-21-at-15.40.05-768x402.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21154030/Screenshot-2025-04-21-at-15.40.05.png 1490w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44904179/wall-street-sinks-dollar-slides-as-trump-ramps-up-fed-attacks-whats-driving-markets-monday">Wall Street Sinks, Dollar Slides As Trump Ramps Up Fed Attacks: What&#8217;s Driving Markets Monday?</a></li>
</ul>
Photo: Shutterstock.

Travel

Movers

What's Going On With Boeing Shares Today?

FFNW

First Financial Northwest Board Declares Initial Liquidating Distribution Of $22/Share Or $203M, Representing ~95% Of Anticipated Proceeds To Ultimately Be Distributed

Ryan Specialty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYAN#NYSE">RYAN</a>) ("Ryan Specialty"), a leading international specialty insurance firm, is pleased to announce that it has signed a definitive agreement to acquire certain assets of USQRisk Holdings, LLC ("USQ"). USQ will become a part of the alternative risk business within Ryan Specialty.
Terms of the transaction were not disclosed. The acquisition is expected to close during the second quarter of 2025.
The acquisition brings approximately $11 million of incremental operating revenue to Ryan Specialty, based on the 12 months ended December 31, 2024. This figure has not been audited. &nbsp;

RYAN

Ryan Specialty Signs Definitive Agreement To Acquire Certain Assets Of USQRisk Holdings; Terms Not Disclosed; Deal Expected To Close In Q2, 2025

Calix, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) today announced that its board of directors increased the authorization to repurchase the Company's common stock by an additional $100 million under the existing stock repurchase program.
Under the repurchase program, repurchases can be made from time to time using a variety of methods, which may include open market purchases, privately negotiated transactions or otherwise, all in accordance with the rules of the Securities and Exchange Commission and other applicable legal requirements. The specific timing, price and size of the purchases will depend on prevailing stock prices, general economic and market conditions, and other considerations consistent with the Company's capital allocation strategy. The stock repurchase program does not obligate Calix to purchase any dollar amount or number of shares of common stock and the program may be suspended or discontinued at any time.

Buybacks

CALX

Calix Increases Stock Repurchase Authorization By Additional $100M Under Existing Stock Repurchase Program

WR Berkley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) reported quarterly earnings of $1.01 per share which beat the analyst consensus estimate of $0.98 by 3.06 percent. This is a 2.88 percent decrease over earnings of $1.04 per share from the same period last year. The company reported quarterly sales of $3.55 billion which beat the analyst consensus estimate of $3.53 billion by 0.47 percent. This is a 8.92 percent increase over sales of $3.26 billion the same period last year.

Earnings Beats

WR Berkley Q1 Adj $1.01 Beats $0.98 Estimate, Sales $3.55B Beat $3.53B Estimate

President Donald Trump&#8216;s <a href="https://www.benzinga.com/government/regulations/25/04/44896834/dollar-hits-3-year-lows-us-stocks-tumble-as-trump-threatens-to-fire-powell-contrarians-of-the-world-unite">mounting fierce criticism</a> against Federal Reserve Chair Jerome Powell is unnerving the marker and taking down tech juggernaut Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>). 
Still, there may be a chance to extract quick profits for bold and opportunistic traders.
To be clear, no one should dismiss the anxiety surrounding the latest market rumblings. In a Truth Social post, Trump previously signaled discouraging intentions for the Fed chair. 
"Jerome Powell is always too late and wrong. His termination cannot come fast enough,&#8221; Trump said.
Trump initially nominated Powell in 2017. President Joe Biden appointed Powell to another four-year term in 2022. U.S. presidents do not have the legal authority to fire a Fed chairman before the end of a term, which for Powell is May 2026.
At the heart of the matter is the benchmark interest rate, with Trump blasting Powell for not cutting borrowing costs despite falling oil prices and easing inflation concerns. The president further <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44875406/hell-be-out-if-i-ask-him-can-trumps-threat-to-oust-powell-shake-the-fed">stoked the flames of discontent</a>, remarking during a public appearance with Italian Prime Minister Giorgia Meloni that he could remove Powell "real fast" if he so wished.
Of course, the political drama only underscores a far more pressing concern: the White House's economic policies — particularly related to tariffs against key economic partners — threatens to <a href="https://www.benzinga.com/news/global/25/04/44899617/90-chance-of-recession-due-to-trumps-tariffs-sharp-slowdown-is-coming-economist-says">sink the nation into a recession</a>, potentially sometime this year. For a company like Alphabet, which depends heavily on advertising revenue, a downturn would be problematic; hence, the volatility in Alphabet&#8217;s stock.
Despite the wide-ranging concerns, management has a chance to frame the narrative properly with the company's Thursday after-close <a href="https://www.benzinga.com/quote/GOOG/earnings">earnings disclosure</a>. One area that may convince investors to take a stab at Alphabet stock is the broader integration of artificial intelligence. By embedding AI across products to reduce costs and improve engagement, along with generative AI monetization efforts within the Search platform, the tech giant may help right its own ship.
<h2 class="wp-block-heading">Winners Like Alphabet Don't Stay Deflated for Too Long</h2>
Trump perceives tariffs as key to winning trade deals and often discussed the strategy on the campaign trail. And that's the main takeaway for Alphabet from a stock trading perspective: it's a winner and winners don't stay deflated for too long.
However, with headline metrics such as a year-to-date loss of 22%, it's easy for pessimism to cloud the discourse. Part of the reason for this tendency has to do with the way traditional analyses — whether technical or even fundamental — are structured. Specifically, standard methodologies rely on continuous-time signal processing frameworks. That's a complicated way of saying that there's no such thing as a "good" stock price or "bad" revenue.
Instead, metrics like share price or revenue represent scalar realities: they are what they are. The problem, of course, is that many fall into the trap of interpreting a discrete outcome — for example, "it's a good time to buy" — from a continuous signal without defining what exactly is "good."
To get around this dilemma, investors can deploy a process called abstraction, essentially compressing continuous events into discrete events, thus generating a discrete-event analysis for discrete conclusions. Personally, I deployed a quasi-binary compression for the purposes of calculating a modified first-order Markov chain model on Alphabet stock.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21151826/GOOG-stock-price-projection-1-1024x576.jpg" alt="" class="wp-image-880553" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21151826/GOOG-stock-price-projection-1-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21151826/GOOG-stock-price-projection-1-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21151826/GOOG-stock-price-projection-1-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21151826/GOOG-stock-price-projection-1.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
What I noted was that in the past two months, the shares have printed in totality (meaning not necessarily in order) a "2-8" sequence: two weeks up, eight weeks down. The 2-8 sequence is rare, flashing only four times in the past decade. What's significant in my opinion is that in three out of the four cases, Alphabet popped sharply higher within the first two weeks of the 2-8 signal flashing.
In any other circumstance, one would consider the above assessment statistically fragile. But price action tends to marshal human emotions, which may lend credibility to this potential upside pivot.
<h2 class="wp-block-heading">Plotting a Bullish Strategy for Alphabet</h2>
With the prospect of a bullish reversal on the horizon — and especially with an earnings report coming — bold traders may be enticed to consider an out-the-money (OTM) wager as opposed to a hedged bet. Every good quarterback knows when it's time to go deep and this might be such a moment.
At this moment, the cheapest vertical spread which in my view touches the boundaries of rationality is the 157.50/160 bull call spread for the options chain expiring May 2. This transaction involves buying the $157.50 call (at an ask of $265) and simultaneously selling the $160 call (at a bid of $193), resulting in a net debit paid of $72, the most that can be lost in the trade.
Should GOOG stock rise through the $160 short strike price at expiration, the maximum reward is $178, or a payout of over 247%.
It's a highly speculative, capped-risk, capped-reward setup. The justification for the trade is that in 75% of the time when the 2-8 sequence flashes, the median return (under the positive pathway) two weeks out is 13.15%. Coincidentally, the timing of the earnings release lends loose support to the speculation that something special could be cooking for Alphabet stock.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44909343/speculators-ramp-up-bets-on-who-will-succeed-fed-chair-powell-as-trumps-pressure-campaign-intensifies">Speculators Ramp Up Bets On Who Will Succeed Fed Chair Powell As Trump&#8217;s Pressure Campaign Intensifies</a></li>
</ul>
Image: Shutterstock

Equities

Long Ideas

Options

Politics

GOOG

GOOGL

Options Corner: Monday Blues Can't Hide Alphabet Stock's Potential Upside Pivot

NYSE American LLC ("NYSE American" or the "Exchange") announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Scorpius Holdings, Inc. (the "Company") — ticker symbol SCPX — from NYSE American. Trading in the Company's common stock will be suspended immediately.
NYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the Company's common stock.
The Company has a right to a review of the staff's determination to delist the Company's common stock by the Listings Qualifications Panel of the Committee for Review of the Board of Directors of the Exchange. The NYSE American will apply to the Securities and Exchange Commission to delist the Company's common stock upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff's decision.

SCPX

NYSE American To Commence Delisting Proceedings Against Scorpius Holdings, Inc.

Management

AEON

AEON Biopharma Appoints Rob Bancroft As President And Chief Executive Officer, Effective April 29, 2025

BOK Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOKF#NASDAQ">BOKF</a>) reported quarterly earnings of $1.86 per share which missed the analyst consensus estimate of $2.00 by 7 percent. This is a 2.62 percent decrease over earnings of $1.91 per share from the same period last year.

BOKF

BOK Financial Q1 EPS $1.86 Misses $2.00 Estimate

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.veracyte.com%2F&amp;esheet=54240820&amp;newsitemid=20250420178680&amp;lan=en-US&amp;anchor=Veracyte%2C+Inc&amp;index=1&amp;md5=bcb97a0a3c8892614f1297db580584e5">Veracyte, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), a leading cancer diagnostics company, today announced that data from its market-leading Decipher Prostate Genomic Classifier are available in a new specialized database that the National Cancer Institute's (NCI's) Surveillance, Epidemiology, and End Results (SEER) Program <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fseer.cancer.gov%2Fdata%2Fspecialized%2Favailable-databases%2Fdecipher-prostate-gc-request%2F&amp;esheet=54240820&amp;newsitemid=20250420178680&amp;lan=en-US&amp;anchor=just+released&amp;index=2&amp;md5=85917c7b4d1ecea2f5d8dfbbb5a0ff09">just released</a>. This database will enable eligible researchers to evaluate Decipher Prostate test results in the context of real-world patient outcomes, prostate cancer characteristics, treatment protocols, demographics and other factors.
 &nbsp;

VCYT

Veracyte Says Data From Decipher Prostate Genomic Classifier Are Linked to Real-World Data in NCI's SEER Specialized Database Release

Metropolitan Bank Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCB#NYSE">MCB</a>) reported quarterly earnings of $1.45 per share which beat the analyst consensus estimate of $1.35 by 7.41 percent. This is a 0.68 percent decrease over earnings of $1.46 per share from the same period last year. The company reported quarterly sales of $70.590 million which beat the analyst consensus estimate of $67.626 million by 4.38 percent. This is a 5.81 percent increase over sales of $66.713 million the same period last year.

Metropolitan Bank Holding Q1 2025 GAAP EPS $1.45 Beats $1.35 Estimate, Sales $70.590M Beat $67.626M Estimate

SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=MSbrdBsxJ0qK1Hj5j32O9kSuaaIEPlFy7PmtIxywiqqk-HPG63iZ18NRE68gahrcwR8IxrDuxFrLIitrFhXrGbD9WKdetDrUMBGMYHQM9_U=">Myriad Genetics, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of Clinical Psychopharmacology has published a <a href="https://www.globenewswire.com/Tracker?data=EVbdMn8J2O5vDqy9XKemwDnKWY8ibd26P1rodSxpoEe9EWW2WGtweVF3EV9dgVhX4Oq6dnoddPY_isYVst4Gl2FKQiEWskHCUAd1lHqBuo_rZ7j8CjyLYZHU-R_7QEmiYRZGkxNwACJ6cEH3TUxJAwFUEuEFbpd-Blm35t_dXbzee7er-FNleB_elq4rxm3sqvjUX-LWUdYM7TPlTviNUw==">study</a> showing those with major depressive disorder had fewer psychiatric hospitalizations after taking the <a href="https://www.globenewswire.com/Tracker?data=PfxZJVr4wc8HUvRb9IBcvYvJgAw8uqyk1tq6nkURzvry5u4pdhG62_gnKxXfX7I4RS6dqH7ZQ2NSIk_NquRfFw==">GeneSight</a>&#xAE; Psychotropic Test.
"Millions of Americans face major depressive disorder each year, and the GeneSight test provides genetic insights that may help healthcare providers personalize the selection of mental health medications," said Dale Muzzey, PhD, Chief Scientific Officer at Myriad Genetics. "This study found lower psychiatric-related hospitalizations following use of the GeneSight test, suggesting that GeneSight may help healthcare providers identify effective medications and reduce the trial-and-error prescribing process that can lead to increased healthcare resource utilization."
The publication includes additional analysis of the study results first&nbsp;<a href="https://www.globenewswire.com/Tracker?data=aawoQwA-i27wRPhv0IckRGvSsR97UwileLPHExF26qW015wldfgv0mxsK05eC7fx6CMt58v0EoB97rF_nlp5qIu2P65PNdDGuc6Q1UIE93qyFFWalQEZl1o3SPkM8oIFn4CsVaHKr2dJ1POVGYFKpA==">shared</a> at the 2024 American Association of Psychiatric Pharmacists conference. The study, entitled "Real-World Impact of Pharmacogenomic Testing on Medication Use and Healthcare Resource Utilization in Patients with Major Depressive Disorder," showed, following GeneSight testing:
<ul>
<li>There was an almost 40% relative reduction in the proportion of patients who filled prescriptions with significant gene-drug interactions. We believe these data suggest that healthcare providers are using the GeneSight test to inform treatment decisions.</li>
<li>A 39% relative reduction in psychiatric-related hospitalizations and a 29% relative reduction in hospitalizations for any reason were observed.</li>
<li>Patients who were switched to medications with no/moderate gene-drug interactions had a 44% relative reduction in psychiatric hospitalizations and a 34% relative reduction in hospitalizations for any reason. &nbsp;</li>
</ul>
"As a practicing psychiatrist, this study reinforces my decision to order the GeneSight test for my patients. Many patients don't respond well to the first prescribed medication and the rate of positive medication response declines after that1," said Dr. Crystal Nelson, a psychiatrist in Newnan, GA. "My patients who suffer from major depressive disorder often share a renewed sense of hope after I tell them about and order the GeneSight test. Many of them share that they are relieved to learn that genetics may have been a reason why a medication failed them."
_______________ 1 American Journal of Psychiatry. "Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR&#x2A;D report" <a href="https://www.globenewswire.com/Tracker?data=RgRQa9K9caAn3yx1f0CpDJ-mVM1CWZkP24POoIhuIJoCv77GBMX0cASQPmbRoS9pvHJq1FXz-lWstgigaHbrhYUs27HC6eogmlDS_OM7Z4n1W1aKlU6gnoFUULUmpfHtq1HYLWE5FplAwUnzrtiDVQ==">https://pubmed.ncbi.nlm.nih.gov/17074942/</a> &nbsp;
About the Study The study analyzed a dataset generated by linking more than a half million de-identified patients who received the GeneSight test to administrative insurance claims from a nationwide data warehouse in the United States. Nearly 21,000 patients with major depressive disorder met inclusion criteria to be included in the study. The study authors then evaluated this dataset with regard to medications prescribed before and after GeneSight testing, as well as healthcare resource utilization before and after GeneSight testing. The company believes that GeneSight testing contributed to the reduction in patients who filled prescriptions with significant gene-drug interactions and the reduction in hospitalizations, but the study did not include an analysis of a non-GeneSight control group to evaluate whether or to what extent GeneSight testing was the cause of these reductions.

Biotech

General

MYGN

Myriad Genetics Releases Study Results That Shows Patients With Depression Had Fewer Psychiatric Hospitalizations After GeneSight Testing

APPN

Appian Appoints Serge Tanjga As CFO, Effective May 27

Servisfirst Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SFBS#NYSE">SFBS</a>) reported quarterly earnings of $1.16 per share which missed the analyst consensus estimate of $1.18 by 1.69 percent. This is a 23.4 percent increase over earnings of $0.94 per share from the same period last year.

SFBS

Servisfirst Bancshares Q1 Adj $1.16 Misses $1.18 Estimate

XAIR

Beyond Air's NeuroNOS Subsidiary Receives FDA Orphan Drug Designation For Phelan-McDermid Syndrome

CSWC

Capital Southwest Corporation Subsidiary Receives US Small Business Administration License To Operate Small Business Investment Company

JP Morgan analyst Arun Jayaram trimmed the price forecast for Liberty Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) following first-quarter<a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener"> results reported last week</a>.
Liberty Energy reported quarterly earnings of 4 cents per share, which missed the analyst consensus estimate of 5 cents per share, and sales of $977.46 million, which beat the analyst <a target="_blank" href="https://www.benzinga.com/25/04/44858147/why-liberty-energy-shares-are-trading-higher-by-9-here-are-20-stocks-moving-premarket" rel="noreferrer noopener">consensus estimate of $954.73 million</a>.
The company notes that a temporary pause in tariffs has eased economic pressure and reduced<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44853604/liberty-energy-inc-announces-first-quarter-2025-financial-and-operational-results" rel="noreferrer noopener"> immediate concerns about oil demand</a>.
Nonetheless, the management notes that the attention remains on supply factors, including shifts in OPEC+ strategy and potential export constraints from Iran, Russia, and Venezuela.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44564627/liberty-energy-1q-earnings-preview-and-key-takeaways-from-meeting-management-team" rel="noreferrer noopener">Liberty Energy 1Q Earnings Preview And Key Takeaways From Meeting Management Team</a>
While commodity price volatility hasn&#8217;t yet shifted North American production plans, management expects oil producers<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> to assess potential impacts on pricing</a>.
Jayaram slashed the price forecast from $18 to $16 <a target="_blank" href="https://www.benzinga.com/quote/LBRT/analyst-ratings" rel="noreferrer noopener">while reiterating a Neutral rating</a>.
The analyst says that the company&#8217;s outlook reflects strong momentum from the first quarter to continue into the second quarter of FY25.
Activity levels are likely to remain stable for Publics and larger operators, which make up LBRT's primary customer base, adds the analyst.
Nevertheless, Jayaram writes that there may be emerging risks to activity in the second half of 2025.
The analyst slightly lowered the second-quarter EBITDA estimates to $173 million (up 2.9% quarter-over-quarter) from the previous estimate of $175 million.
The revision brings the estimate just below the mid-single-digit sequential EBITDA growth that management indicated during the earnings call, the analyst adds.
Also, Jayaram lowered the 2025/2026 EBITDA estimates to $680 million/$703 million (from $702 million/$839 million previously), and FCF generation estimates to $72 million/$26 million (from $31 million/$88 million earlier).
Price Action: LBRT shares were down 4.4% at $11.54 on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/04/44793519/energy-secretary-chris-wright-is-bullish-as-oil-prices-crater" target="_blank" rel="noreferrer noopener">Energy Secretary Chris Wright Is &#8216;Bullish&#8217; As Oil Prices Crater</a></li>
</ul>
Photo: katjen/Shutterstock

Price Target

Small Cap

LBRT

Liberty Energy's Momentum Carries Into Q2 As JPMorgan Tracks Growing Supply-Side Risks

CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that it will present an update on the progress of its DT-168 program for Fuchs endothelial corneal dystrophy (FECD) at Eyecelerator @ Park City 2025 on Friday, May 2, 2025, at 1:30 p.m. MT in Park City, UT. The presentation will include safety findings from the Phase 1 single- and multiple-ascending dose trial of DT-168 in healthy adult volunteers and plans for Phase 2 clinical development in FECD patients.
DT-168 is a GeneTAC&#xAE; small molecule, formulated as an eye drop, that is designed to selectively target the CTG repeat expansion in the TCF4 gene and reduce the expression of the mutant gene product that causes corneal endothelial cell dysfunction leading to FECD.

DSGN

Design Therapeutics To Present Update On Progress Of DT-168 Program For FECD At Eyecelerator At Park City 2025 On May 2, 2025

AGNC Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGNC#NASDAQ">AGNC</a>) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.40 by 10 percent. This is a 24.14 percent decrease over earnings of $0.58 per share from the same period last year.

AGNC

AGNC Investment Q1 Adj $0.44 Beats $0.40 Estimate

Health Care

Press Releases

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Technical Explosions: DUO, KTTA, TBIO, GOTU – Watch Peraso Inc. (NASDAQ: PRSO) Now Amid Breakout Momentum!

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

Power Nickel's (TSX.V: PNPN) Hole Delivers "BIG"- Gold Terra (TSX.V: YGT) Developments and Exploration Progress Reported – More Stocks Inside!

Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Comments

Pasithea Therapeutics

Pasithea Therapeutics (KTTA) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO